Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.
Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q4 and full‑year 2025 results and a corporate update on March 9, 2026. Key clinical highlights: CRB-701 showed encouraging unconfirmed ORRs (HNSCC 47.6%, cervical 37.5%, bladder 55.6%) and has FDA Fast Track designations. CRB-913 showed 2.9% placebo‑adjusted weight loss at 14 days with favorable GI and neuropsychiatric profiles. Financially, Corbus completed a $75M public offering in Q4 2025 and held $163.3M cash, funding operations into 2028. Anticipated catalysts: CRB-701 and CRB-913 mid‑2026 data readouts; CRB-701 registrational discussions update in Q1 2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will present a corporate overview and hold investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference.
The event is virtual on February 25, 2026 with a presentation at 3:20 PM ET; a webcast link will be provided for investors.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for January 15, 2026 at 8:15 a.m. PST / 11:15 a.m. EST. The company will participate in a presentation and one-on-one investor meetings, and a webcast will be available.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Phase 1a single- and multiple-ascending dose results for oral CB1 inverse agonist CRB-913 in obesity on Dec 11, 2025. The study (SAD n=64; MAD n=48) showed no serious treatment-emergent adverse events, minimal GI effects, and stable daily neuropsychiatric assessments (CSSRS, PHQ-9, GAD-7). In a dedicated obese MAD cohort (150 mg QD, n=12), all 9 treated participants lost weight vs 0/3 placebo, with a placebo-adjusted mean weight loss of 2.9% at Day 14 (individual range 1.3%–4.3%). PK supported once-daily oral dosing. A 12-week Phase 1b dose-finding study (CANYON-1) has been initiated, with completion expected in summer 2026. The company will host a conference call and webcast today at 8:00 am ET.
Corbus Pharmaceuticals (NASDAQ: CRBP) will release results from its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of oral CB1 inverse agonist CRB-913 before market open on Thursday, December 11, 2025.
The company will host a conference call and live webcast at 8:00 am ET the same day to review the Phase 1a safety and tolerability data; a replay will be available on the Corbus website.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q3 2025 results and a corporate update on Nov 12, 2025. The company presented CRB-701 dose-optimization data at ESMO 2025 showing ORRs at 3.6 mg/kg of 47.6% in HNSCC, 37.5% in cervical cancer, and 55.6% in bladder cancer. Corbus plans an FDA meeting in Q1 2026 and expects to start a Phase 2/3 registrational study by mid-2026; CRB-701 has Fast Track designation for HNSCC and metastatic cervical cancer.
The company closed a public offering raising net proceeds of approximately $73.8M (total offering $75M), reporting $104.0M cash on 9/30/25 and stating runway into 2028. CRB-913 SAD/MAD readout and Phase 1b start expected by end of 2025. Q3 net loss was $23.3M versus $13.8M a year earlier.
Corbus Pharmaceuticals (Nasdaq: CRBP) will participate in three investor conferences in November–December 2025 with presentations and one-on-one meetings.
Schedule: Guggenheim Healthcare Innovation Conference in Boston on Nov 12, 2025 at 1:00 PM ET; Jefferies Global Healthcare Conference in London on Nov 18, 2025 at 4:00 PM GMT; Evercore 8th Annual Healthcare Conference in Miami on Dec 2, 2025 at 3:50 PM ET. Each event will offer a webcast (links provided by the company).
Corbus Pharmaceuticals (Nasdaq: CRBP) priced an underwritten public offering to raise approximately $75 million before underwriting discounts and expenses. The offering consists of 4,744,231 shares of common stock and pre-funded warrants to purchase 1,025,000 shares at $12.9999 each, with an exercise price of $0.0001 per share. Underwriters have a 30-day option for up to 865,384 additional shares. Closing is expected on or about November 3, 2025. Proceeds are intended to fund clinical development, working capital, and general corporate purposes.
Corbus Pharmaceuticals (Nasdaq: CRBP) announced on Oct 30, 2025 a proposed underwritten public offering of its common stock and, for certain investors, pre-funded warrants to purchase common stock. All securities will be sold by Corbus, and the offering is subject to market conditions with no assurance of completion, size, or terms.
Corbus said it intends to use net proceeds to fund clinical development of its pipeline and for working capital and general corporate purposes. Jefferies and Piper Sandler are joint book-running managers, and underwriters may receive a 30-day option to buy up to an additional 15% of the shares. A registration statement became effective on Mar 20, 2024.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Phase 1/2 CRB-701 (SYS6002) data presented at ESMO25 showing clinical activity and a manageable safety profile.
In response-evaluable patients dosed at 3.6 mg/kg, CRB-701 produced ORR 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in metastatic urothelial cancer. No dose-limiting toxicities were observed; Grade 3 treatment-related adverse events occurred in 18.0%, with no Grade 4/5 events and a 6.0% discontinuation rate. Data cutoff was September 1, 2025 (167 patients enrolled; 84 response-evaluable). The company plans an FDA meeting in 2025 and expects to initiate registrational studies by mid-2026.